Array BioPharma and Amgen Partner in Type 2 Diabetes
- Details
- Category: Amgen
Array BioPharma Inc. (Nasdaq: ARRY) and Amgen Inc.(Nasdaq: AMGN) today announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array's small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes.
Takeda and Pfizer to Co-Promote Takeda's Actos® for the Treatment of Type 2 Diabetes in China
- Details
- Category: Pfizer
Takeda Pharmaceutical Company Limited ("Takeda") and Pfizer Inc. ("Pfizer") announced that they have entered into an agreement under which Pfizer in China will co-promote Takeda's Actos® (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in China.
Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced today a definitive agreement to acquire STARLIMS Technologies Ltd. (Nasdaq: LIMS), a leading provider of laboratory information management systems, for approximately $123 million in cash. The acquisition strengthens Abbott's competitive position in the global diagnostics market, providing advanced web-based applications to help laboratories efficiently store, retrieve and analyze a significantly increasing volume of clinical, managerial and administrative data.
GSK and Intercell form strategic alliance to develop and commercialise innovative vaccines
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline Biologicals SA (GSK) and Intercell announced an agreement to form a strategic alliance to accelerate the development and commercialisation of needle-free, patch-based vaccines. The agreement will include Intercell's candidate vaccine for travellers' diarrhoea (TD) and an investigational single application pandemic influenza vaccine, as well as the use of the patch technology for other vaccines in GSK's portfolio.
Pfizer Extends Commitment to Help Unemployed Americans
- Details
- Category: Pfizer
Pfizer will extend its MAINTAIN™ (Medicines Assistance for Those who Are in Need) patient assistance program for an additional year, through December 31, 2010. In addition to the more than 70 Pfizer primary care medicines currently available through MAINTAIN, Pfizer will extend the benefits of MAINTAIN to many legacy Wyeth medicines.
Physicians More Likely To Report Drug Safety Information Through Electronic Health Records System
- Details
- Category: Pfizer
Pfizer announced today results of a survey the company recently sponsored that shows physicians are more likely to report side effects through an electronic health records (EHR) system, as compared to traditional paper methods.
Novartis Tasigna® trial shows superior results to Glivec®
- Details
- Category: Novartis
In a large Phase III clinical trial, Tasigna® (nilotinib) demonstrated greater efficacy over Glivec® (imatinib)* in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase[1].
More Pharma News ...
- Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab
- Novo Nordisk starts phase 1 trial with oral insulin analogue
- Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University
- New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
- AstraZeneca and Targacept Form Global Collaboration and Licence Agreement
- Resource Guide About Key Issues Facing the Pharmaceutical Industry
- GSK's Arepanrix⢠H1N1 pandemic vaccine prequalified by the World Health Organization